EUVIMEDEUVIMED entdecken
Open Access

Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program

Christina L Aquilante, Katy E Trinkley, Yee Ming Lee, Kristy R Crooks, Emily C Hearst, Simeon M Heckman, Kaitlyn W Hess, Elizabeth L Kudron, James L Martin, Carolyn T Swartz, David P Kao

American Journal of Health-System Pharmacy · 11.06.2024 · 81 (12) · 555-562

DOI: 10.1093/ajhp/zxae008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 22.01.2024. Verfasst von Christina L Aquilante und 10 weiteren Autor:innen. Beteiligte Einrichtung: Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. Hauptthemen laut MEDLINE: Clopidogrel, Decision Support Systems, Clinical, Cytochrome P-450 CYP2C19, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To describe our experiences implementing and iterating CYP2C19 genotype–guided clopidogrel pharmacogenetic clinical decision support (CDS) tools over time in the setting of a large health system–wide, preemptive pharmacogenomics program. Summary Clopidogrel-treated patients who are genetically predicted cytochrome P450 isozyme 2C19 (CYP2C19) intermediate or poor metabolizers have an increased risk of atherothrombotic events, some of which can be life-threatening. The Clinical Pharmacogenetics Implementation Consortium provides guidance for the use of clopidogrel based on CYP2C19 genotype in patients with cardiovascular and cerebrovascular diseases. Our multidisciplinary team implemented an automated, interruptive alert that fires when clopidogrel is ordered or refilled for biobank participants with structured CYP2C19 intermediate or poor metabolizer genomic indicators in the electronic health record. The implementation began with a narrow cardiovascular indication and setting and was then scaled in 4 primary dimensions: (1) clinical indication; (2) availability across health-system locations; (3) care venue (e.g., inpatient vs outpatient); and (4) provider groups (eg, cardiology and neurology). We iterated our approach over time based on evolving clinical evidence and proactive strategies to optimize CDS maintenance and sustainability. A key facilitator of expansion was socialization of the broader pharmacogenomics initiative among our academic medical center community, accompanied by clinician acceptance of pharmacogenetic alerts in practice.

Conclusion

A multidisciplinary collaboration is recommended to facilitate the use of CYP2C19 genotype–guided antiplatelet therapy in patients with cardiovascular and cerebrovascular diseases. Evolving clopidogrel pharmacogenetic evidence necessitates thoughtful iteration of implementation efforts and strategies to optimize long-term maintenance and sustainability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelDecision Support Systems, ClinicalCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsPharmacogeneticsHumansGenotypeCardiovascular DiseasesElectronic Health Records

Stichwörter der Autor:innen

CYP2C19clinical decision supportclopidogrelcytochrome P450 isozyme 2C19implementationpharmacogeneticspharmacogenomics

Substanzen

ClopidogrelCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsCYP2C19 protein, human

Autor:innen und Institutionen

  • Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
  • Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Department of Family Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • UCHealth, Aurora, CO, USA.

Förderung

  • NHLBI NIH HHS
  • NIH

Zitieren

APA

Aquilante, C. L., Trinkley, K. E., Lee, Y. M., Crooks, K. R., Hearst, E. C., Heckman, S. M., Hess, K. W., Kudron, E. L., Martin, J. L., Swartz, C. T., & Kao, D. P. (2024). Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program. American Journal of Health-System Pharmacy, 81(12), 555-562. https://doi.org/10.1093/ajhp/zxae008

Vancouver

Aquilante CL, Trinkley KE, Lee YM, Crooks KR, Hearst EC, Heckman SM, et al. Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program. American Journal of Health-System Pharmacy. 2024;81(12):555-562. doi:10.1093/ajhp/zxae008

BibTeX
@article{Aquilante2024,
  author = {Aquilante, Christina L and Trinkley, Katy E and Lee, Yee Ming and Crooks, Kristy R and Hearst, Emily C and Heckman, Simeon M and Hess, Kaitlyn W and Kudron, Elizabeth L and Martin, James L and Swartz, Carolyn T and Kao, David P},
  title = {Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program},
  journal = {American Journal of Health-System Pharmacy},
  year = {2024},
  volume = {81},
  number = {12},
  pages = {555--562},
  doi = {10.1093/ajhp/zxae008}
}
Kostenlos starten →